Injectable Bioprinted Dermal Matrices for Complex Wound Closure

Abstract

Complex wounds, including chronic ulcers, traumatic injuries, and extensive surgical defects, present significant challenges for clinicians due to impaired healing and high morbidity. Recent advances in regenerative medicine have led to the emergence of injectable bioprinted dermal matrices as a promising modality to facilitate wound closure by mimicking native dermal architecture and promoting tissue regeneration. This review synthesizes current scientific evidence on the mechanisms, clinical applications, and outcomes associated with injectable bioprinted dermal matrices, providing an expert perspective on their role in the management of complex wounds. The discussion encompasses epidemiology, pathophysiology, risk factors, diagnostic strategies, therapeutic approaches, and evidence-based guidelines, offering practical insights for healthcare professionals involved in wound care.

Introduction

Complex wounds represent a substantial burden to patients and healthcare systems worldwide, arising from etiologies such as diabetes, vascular insufficiency, trauma, and oncologic resections. Traditional management often involves debridement, negative pressure therapy, and grafting, yet many wounds fail to heal, underscoring the need for innovative therapeutic strategies. Injectable bioprinted dermal matrices have emerged as a disruptive technology, leveraging advances in 3D bioprinting, biomaterials science, and cell biology to enable minimally invasive delivery of bioactive scaffolds that recapitulate the dermal microenvironment. This article critically reviews the scientific and clinical landscape of injectable bioprinted dermal matrices, elucidating their mechanisms of action, therapeutic efficacy, and implications for practice.

Epidemiology / Disease Burden

Complex wounds affect millions globally, with chronic wounds alone impacting up to 2% of the population in developed nations. Diabetic foot ulcers, venous leg ulcers, and pressure injuries account for the majority of cases, with prevalence rising due to aging populations and increasing rates of diabetes and vascular disease. These wounds are associated with prolonged hospitalization, reduced quality of life, and significant economic costs, with annual expenditures exceeding several billion dollars in healthcare systems such as those in the United States and Europe. The high incidence of complications, including infection and limb loss, further underscores the need for more effective wound closure modalities.

Pathophysiology

Complex wound healing is impeded by a combination of local and systemic factors. Chronic inflammation, impaired angiogenesis, extracellular matrix (ECM) degradation, and cellular senescence disrupt the normal progression of hemostasis, inflammation, proliferation, and remodeling. Inadequate vascular supply, persistent infection, and dysregulated cytokine signaling contribute to the formation of non-healing wounds. Restoration of the ECM and re-establishment of vascular networks are critical for successful tissue regeneration, and these processes are often disrupted in the context of chronic disease or extensive tissue loss.

Risk Factors

Key risk factors for complex wounds include diabetes mellitus, peripheral arterial disease, venous insufficiency, prolonged immobility, advanced age, malnutrition, immunosuppression, and previous wound history. Comorbidities such as obesity and chronic kidney disease further increase susceptibility to impaired healing. Local factors, including repeated trauma, pressure, ischemia, and infection, exacerbate tissue breakdown and hinder reparative processes.

Clinical Features

Complex wounds are characterized by delayed healing, persistent inflammation, necrotic tissue, exudate, and frequent colonization or infection. Clinically, these wounds may display undermined edges, exposed structures (tendon, bone), and a failure to progress through the expected healing stages. Pain, malodor, and functional impairment are common, and complications such as osteomyelitis or sepsis can arise in severe cases.

Diagnosis

Diagnosis of complex wounds involves a thorough clinical assessment, including evaluation of wound size, depth, location, tissue quality, and presence of infection. Adjunctive investigations may include wound cultures, vascular studies (e.g., ankle-brachial index, Doppler ultrasound), and imaging to assess for deep tissue involvement. Laboratory markers of inflammation and glycemic control provide additional context. Emerging techniques such as fluorescence imaging and molecular diagnostics are being explored to better characterize wound microenvironments and guide therapy.

Treatment & Management

The management of complex wounds traditionally involves a combination of wound bed preparation (debridement, infection control), optimization of systemic factors (glycemic control, nutrition), and application of advanced dressings or grafts. Negative pressure wound therapy, growth factor delivery, and skin substitutes have demonstrated variable efficacy. Injectable bioprinted dermal matrices represent a novel approach, offering customizable scaffolds that can be delivered with minimal invasiveness to promote angiogenesis, cellular migration, and ECM deposition. These matrices may be used alone or in conjunction with other modalities, such as autologous cell therapy or biologics, to enhance healing in challenging clinical scenarios.

Recent Advances / Emerging Therapies

Injectable bioprinted dermal matrices harness the precision of 3D bioprinting to create cell-laden or acellular hydrogels that mimic the structure and function of native dermis. Common biomaterials include collagen, gelatin, hyaluronic acid, and fibrin, which may be combined with bioactive molecules (e.g., growth factors, antimicrobial peptides) to enhance regenerative potential. Recent studies have demonstrated that these matrices support neovascularization, modulate inflammation, and facilitate re-epithelialization in preclinical and early clinical settings. The ability to tailor matrix composition and architecture to patient-specific wound characteristics is a distinct advantage, offering the potential for personalized regenerative therapy. Ongoing clinical trials are evaluating the safety and efficacy of these constructs in various wound etiologies, including diabetic ulcers and traumatic injuries.

Guideline Recommendations

Current international guidelines emphasize a multidisciplinary approach to complex wound management, including prompt diagnosis, infection control, and optimization of comorbidities. While bioprinted matrices are not yet universally incorporated into major wound care guidelines, consensus statements from expert panels highlight their promise in refractory cases where conventional therapies have failed. The decision to utilize injectable bioprinted dermal matrices should be individualized, considering wound characteristics, patient comorbidities, and resource availability. Ongoing research and accumulating clinical experience are likely to inform future guideline updates, with the expectation that these technologies will become integral to advanced wound care algorithms as evidence matures.

Conclusion

Injectable bioprinted dermal matrices represent a paradigm shift in the management of complex wounds, offering a minimally invasive, customizable, and biologically active platform to promote tissue regeneration. While early data are promising, further high-quality clinical trials are needed to define optimal indications, protocols, and long-term outcomes. As technology advances and integration into clinical practice expands, these matrices have the potential to improve healing, reduce complications, and enhance quality of life for patients with challenging wounds. Healthcare professionals should remain abreast of emerging evidence and consider these innovative therapies as part of a comprehensive, patient-centered approach to wound care.